Mefenamic acid triggered autoimmune hemolytic anemia in a child: a rare case report

Authors

  • Y. Ravi Kiran Kumar Reddy Department of Paediatrics, Dr. D. Y. Patil Medical College, Hospital and Research Institute, D. Y. Patil Education Society (Deemed to be University), Kolhapur, Maharashtra, India
  • Saiprasad Onkareshwar Kavthekar Department of Paediatrics, Dr. D. Y. Patil Medical College, Hospital and Research Institute, D. Y. Patil Education Society (Deemed to be University), Kolhapur, Maharashtra, India
  • Narahari Venkata Susmitha Department of Paediatrics, Dr. D. Y. Patil Medical College, Hospital and Research Institute, D. Y. Patil Education Society (Deemed to be University), Kolhapur, Maharashtra, India
  • Nivedita Balasaheb Patil Department of Paediatrics, Dr. D. Y. Patil Medical College, Hospital and Research Institute, D. Y. Patil Education Society (Deemed to be University), Kolhapur, Maharashtra, India
  • Priti Kamble Department of Paediatrics, Dr. D. Y. Patil Medical College, Hospital and Research Institute, D. Y. Patil Education Society (Deemed to be University), Kolhapur, Maharashtra, India
  • Chilukuru J. Satyamani Deepika Department of Paediatrics, Dr. D. Y. Patil Medical College, Hospital and Research Institute, D. Y. Patil Education Society (Deemed to be University), Kolhapur, Maharashtra, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20232889

Keywords:

Adverse reaction, AIHA, Children, Mefanamic acid

Abstract

Autoimmune hemolytic anemia (AIHA) is characterized by the abnormal production of antibodies that bind to antigens on the surface of red blood cells (RBC), resulting in RBC destruction. Here we describe a rare case of mefenamic acid-induced AIHA in a 3-year-old boy who developed acute hemolysis after ingestion of mefenamic acid for febrile illness. The aim is to draw the attention of pediatricians to one of the side effects of mefenamic acid, the drug which is very commonly used as an antipyretic.

Metrics

Metrics Loading ...

References

Snapper I, Marks D, Schwartz I, Hollander I. Haemolytic anemia secondary to Mesantoin. Ann Intern Med. 1953;39:619-23.

Schwartz RS, Berkman EM, Silberstein LE. Autoimmune hemolytic anemias. Hematology: Basic Principles and Practice. Ed. RH Hoffman, EJ Benz, SJ Shattil, Jr. Churchill Livingstone, Philadelphia, PA. 2000;611-30.

Moyo VM, Smith D, Brodsky I, Crilley P, Jones RJ, Brodsky RA. High dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood. J Am Society Hematol. 2002;100(2):704-6.

Ware RE, Rose WF. Autoimmune hemolytic anemia. Nathan and Oski's Hematology of Infancy and Childhood, DG Nathan, SH Orkin. Saunders, Philadelphia, PA. 1998;499-522.

Beutler E, Luzzatto L. Hemolytic anemia. Semin Hematol. 1999;36:38-47.

Jefferies LC. Transfusion therapy in autoimmune hemolytic anemia. Hematol Oncol Clin North Am. 1994;8:1087-104.

Garratty G, Arndt PA. An update on drug indued immune hemolytic anemia. Immunohematology. 2007;23:105-19.

LD Petz. Drug induced immune hemolytic anemia. Clin Haematol. 1980;9:455-88.

Mishra R, Pradhan S, Mishra M. Mefenamic acid induced autoimmune hemolytic anemia- A case report. J Med Res. 2020;6(3):67-9.

Roback JD, Barclay S, Hillyer CD. An automatable format for accurate immunohematology testing by flow cytometry. Transfusion. 2003;43:918-27.

Downloads

Published

2023-09-27

How to Cite

Kiran Kumar Reddy, Y. R., Kavthekar, S. O., Venkata Susmitha, N., Patil, N. B., Kamble, P., & Deepika, C. J. S. (2023). Mefenamic acid triggered autoimmune hemolytic anemia in a child: a rare case report. International Journal of Contemporary Pediatrics, 10(10), 1587–1589. https://doi.org/10.18203/2349-3291.ijcp20232889

Issue

Vol. 10 No. 10 (2023): October 2023

Section

Case Reports
Crossref
Scopus
Google Scholar
Europe PMC